From: Advanced glycation endproducts and their receptor in different body compartments in COPD
A. Associations of AGEs with COPD and lung function | |||||||||||
Dependent variables | Predictor variables | ||||||||||
 |  | COPD, n/y | FEV1, % predicted | FEV1/FVC (%) | RV/TLC (%) | FEF25-75, % predicted | |||||
 |  | β | p-value | β | p-value | β | p-value | β | p-value | β | p-value |
Plasma | CEL | 0.009 | 0.924 | -0.465 | 0.642 | 0.581 | 0.562 | 0.117 | 0.204 | 0.0.41 | 0.635 |
 | CML | 0.093 | 0.327 | -0.081 | 0.283 | -0.088 | 0.337 | 0.052 | 0.572 | -0.027 | 0.761 |
 | Pentosidine | -0.035 | 0.711 | -0.020 | 0.788 | 0.069 | 0.451 | 0.093 | 0.314 | -0.011 | 0.901 |
Sputum | CEL | 0.093 | 0.311 | -0.139 | 0.101 | -0.044 | 0.691 | 0.11 | 0.353 | -0.059 | 0.518 |
 | CML | 0.029 | 0.757 | -0.030 | 0.728 | 0.043 | 0.706 | 0.021 | 0.862 | 0.000 | 0.998 |
 | Pentosidine | -0.025 | 0.792 | -0.124 | 0.152 | 0.022 | 0.844 | -0.024 | 0.841 | -0.053 | 0.568 |
Bronchial biopsies | AGE positivity | -0.065 | 0.550 | 0.139 | 0.155 | 0.075 | 0.551 | -0.126 | 0.420 | 0.094 | 0.379 |
Skin | SAF | 0.426 | <0.001 | -0.302 | <0.001 | -0.357 | <0.001 | 0.265 | <0.001 | -0.347 | <0.001 |
B. Associations of RAGE with COPD and lung function | |||||||||||
Dependent variables | Predictor variables | ||||||||||
 |  | COPD, n/y | FEV1, % predicted | FEV1/FVC (%) | RV/TLC (%) | FEF25-75, % predicted | |||||
 |  | β | p-value | β | p-value | β | p-value | β | p-value | β | p-value |
Plasma | sRAGE | -0.422 | <0.001 | 0.310 | <0.001 | 0.405 | <0.001 | -0.236 | 0.002 | 0.297 | <0.001 |
Sputum | sRAGE | -0.110 | 0.194 | 0.084 | 0.289 | 0.012 | 0.908 | -0.015 | 0.895 | -0.041 | 0.622 |
Bronchial biopsies | RAGE positivity | -0.083 | 0.365 | -0.053 | 0.529 | 0.04 | 0.715 | 0.241 | 0.060 | -0.038 | 0.678 |